You are here
Temasek helps drugstore giant Watsons flaunt its glow
TEMASEK is helping a drugstore giant flaunt its glow. The Singapore state investor may sell some of its 25 per cent stake in health and beauty heavyweight A S Watson, Reuters says. The retailer's size, moves upmarket in the mainland, and growth elsewhere in Asia could justify a premium to rivals.
The investment behemoth's 2014 move into A S Watson was a bold - and pricey - bet on consumers. It is still the only other significant shareholder in a retail group at the heart of the CK Hutchison conglomerate, founded by Hong Kong tycoon Li Ka-shing. Now the world's largest drugstore chain, the group has outlets in two dozen markets worldwide, including the flagship Watsons at home, plus supermarkets and beverage-makers.
Watson's global reach and growth prospects did not come cheap. Temasek splashed out some US$5.7 billion for a quarter of the business and a say on the board, amounting to an enterprise value equivalent to a punchy 13 times that year's EBITDA, Goldman Sachs reckons. Mr Li's reputation for selling at the top, as well as rising competition from e-commerce, made that even bolder. Even today, US peer Walgreens Boots Alliance trades at around nine times this year's forecast EBITDA, Refinitiv data shows.
There are still grounds to justify a rich price tag - the retailer's sales topped US$10.7 billion in the six months to June, up a healthy 14 per cent year-on-year.
And the group continues to outperform rival brick-and-mortar chains in terms of profitability, thanks in part to significant own-brand sales. EBITDA margins for health and beauty, for example, have stayed at an impressive 10 per cent.
Fast-growing markets such as Thailand, Philippines and Malaysia are powering growth. Moreover, Watson's health and beauty business in China, which accounted for a third of the group's total EBITDA, is also experiencing a revival, with aggressive store expansion, online partnerships and more white-label goods. The business as a whole managed to increase EBITDA by 13 per cent year-on-year in the six months to June, compared to a 7 per cent annual contraction in 2017.
Taking some money off the table now is shrewd for Temasek.
The question is whether cashed-up private-equity outfits or others will be tempted to the checkout. REUTERS